[144] Jazz Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Jazz Pharmaceuticals submitted a Form 144 reporting a proposed sale of 3,731 common shares on NASDAQ through ETRADE FINANCIAL CORPORATION, with an aggregate market value of $417,872.00. The shares were acquired via restricted stock vesting on 08/07/2025 and the approximate date of sale is listed as 08/08/2025. The filing lists 60,658,809 shares outstanding, so the proposed sale represents a very small fraction of the company’s equity. The record shows Nothing to Report for securities sold in the past three months and lists the nature of payment as COMPENSATION. The notice includes the standard attestation that the seller is not aware of undisclosed material adverse information.

Insights

Financial Analyst

Small insider sale of vested restricted shares; immaterial to capitalization and likely neutral for investors.

The filing documents a proposed sale of 3,731 shares valued at $417,872.00 against 60,658,809 shares outstanding, representing roughly 0.006% of total outstanding stock. Because the securities were acquired by restricted stock vesting and marked as COMPENSATION, this is a routine post-vesting disposition. No sales were reported in the prior three months. From a financial-impact perspective, the size and timing indicate no material effect on capitalization or market supply, so the disclosure is informational rather than market-moving.

Corporate Governance Expert

Insider sale via broker after vesting; filing includes standard seller attestation and shows no recent dispositions.

The Form 144 identifies the broker as ETRADE FINANCIAL CORPORATION and specifies acquisition by restricted stock vesting on 08/07/2025 with an approximate sale date of 08/08/2025. The form records Nothing to Report for prior three-month sales and includes the required representation about knowledge of material adverse information. These are normal governance disclosures for a post-vesting sale and do not raise immediate compliance or governance concerns based solely on the reported facts.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	ETRADE FINANCIAL CORPORATION ETRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 30005	3731	417872.00	60658809	08/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	08/07/2025	RESTRICTED STOCK VESTING	ISSUER			3731	08/07/2025	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the JAZZ Form 144 report?

The filing reports a proposed sale of 3,731 common shares of Jazz Pharmaceuticals with an aggregate market value of $417,872.00.

How were the shares acquired according to the form?

The securities were acquired by restricted stock vesting on 08/07/2025 and the nature of payment is listed as COMPENSATION.

When is the approximate sale date listed on the Form 144?

The approximate date of sale is listed as 08/08/2025.

Through which broker will the JAZZ shares be sold?

The broker named is ETRADE FINANCIAL CORPORATION (address shown in the filing).

Does the filing show any securities sold in the past three months?

No. The filing indicates Nothing to Report for securities sold during the past three months.

How large is the proposed sale relative to JAZZ's outstanding shares?

The filing lists 60,658,809 shares outstanding; the proposed sale of 3,731 shares is a very small fraction of outstanding stock.